Thai-Yen Ling, Taiwan

Academic Degrees Ph.D.: Institute of Agriculture Chemistry, National Taiwan University, Taipei, Taiwan. Professional Career  Committee Member, Asian Cellular Therapy Organization (ACTO) 2023 to present.  ACTO, ATCO TIMES, Editorial Board Members. 2024 to present  Member of Director Board, Taiwan Society for Stem Cells Research (TSSCR), 2012 to present.  Member of Director Board, Formosan Association of Regenerative Medicine, 2021 to present.  Member of Director Board, Taiwan Association of Cell Therapy (TACT), 2020 to present.  Committee Member, Ministry of Health and Welfare (MOHW), Taiwan (衛福部 醫事司細胞治 療特管辦法定價委員會), 2019 to present.  認證委員, 診所細胞治療品質認證，財團法人醫院評鑑暨醫療品質策進會, 2020 to 2022.  110年度/111年度「南部精準健康產業聚落發展推動計畫」審查委員.  Committee Member, Regenerative Medicine Consultation Board, TFDA, Ministry of Health and Welfare (MOHW), Taiwan (衛福部 食品藥物管理署再生醫學諮議小組), 2020 to 2022.  Secretary in General, Taiwan Association of Cell Therapy (TACT), 2014 to 2020.  Member of Director Board, Formosan Association of Regenerative Medicine, 20015 to 2019.  Member of Supervisor Board, Formosan Association of Regenerative Medicine, 20010 to 2015.  Secretary in General, Taiwan Society for Stem Cells Research (TSSCR), 2009 to 2011.  Postdoctoral Fellow: 2005-2006; Genomics Research Center, Academia Sinica, Taipei, Taiwan.  Postdoctoral Fellow:2003-2005; Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.  Postdoctoral Fellow: 2000-2002; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan. Honor  2025年 未來科技獎  第19屆(2022年)國家新創獎 -新創精進獎  第18屆(2021年)國家新創獎 -學研新創  第17屆(2020年)國家新創獎 -新創精進獎  第16屆(2019年)國家新創獎 -學研新創  2012- ISSCR Travel Ward  Honorable Mention Award for “Competition for Originality in Biotechnology”: by the Industrial Development Bureau, Ministry of Economic Affairs, 2009.  Post-doctoral research fellow scholarship, Academia Sinica 2003-2005. Publication (5 years selected) 1. Lu YT, Chen TY, Lin HH, Chen YW, Lin YX, Le DC, Huang YH, Wang AH, Lee CC, Ling TY. Small Extracellular Vesicles Engineered Using Click Chemistry to Express Chimeric Antigen Receptors Show Enhanced Efficacy in Acute Liver Failure. J Extracell Vesicles. 2025 Feb;14(2):e70044. 2. Le DC, Ngo MT, Kuo YC, Chen SH, Lin CY, Ling TY, Pham QTT, Au HK, Myung J, Huang YH. Secretome from estrogen-responding human placenta-derived mesenchymal stem cells rescues ovarian function and circadian rhythm in mice with cyclophosphamide-induced primary ovarian insufficiency. J Biomed Sci. 2024 Oct 11;31(1):95. 3. Lai HC, Huang HH, Hao YJ, Lee HL, Wang CC, Ling TY, Wu JK, Tseng FG. A Preliminary Analysis of Circulating Tumor Microemboli from Breast Cancer Patients during Follow-Up Visits. Curr Oncol. 2024 Sep 21;31(9):5677-5693. 4. Lin TJ, Cheng KC, Wu LY, Lai WY, Ling TY, Kuo YC, Huang YH. Corrigendum: Potential of cellular therapy for ALS: current strategies and future prospects. Front Cell Dev Biol. 2023 Sep 19;11:1292681. doi: 10.3389/fcell.2023.1292681. Erratum for: Front Cell Dev Biol. 2022 Mar 16;10:851613. 5. Liu JF, Chen PC, Ling TY, Hou CH. Hyperthermia increases HSP production in human PDMCs by stimulating ROS formation, p38 MAPK and Akt signaling, and increasing HSF1 activity. Stem Cell Res Ther. 2022 Jun 3;13(1):236. 6. Lin TJ, Cheng GC, Wu LY, Lai WY, Ling TY, Kuo YC, Huang YH. Potential of Cellular Therapy for ALS: Current Strategies and Future Prospects. Front Cell Dev Biol. 2022 Mar 16;10:851613. 7. Tung YC, Wang CK, Huang YK, Huang CK, Peng CC, Patra B, Chen HK, Tsao PN, Ling TY. Identifying distinct oxygen diffusivity through type I pneumocyte-like cell layers using microfluidic device. Talanta. 2022 Jan 1;236:122882. 8. Au HK, Peng SW, Guo CL, Lin CC, Wang YL, Kuo YC, Law TY, Ho HN, Ling TY, Huang YH. Niche Laminin and IGF-1 Additively Coordinate the Maintenance of Oct-4 Through CD49f/IGF-1R-Hif-2α Feedforward Loop in Mouse Germline Stem Cells. Front Cell Dev Biol. 2021 Jul 26;9:646644. 9. Ngo MT, Peng SW, Kuo YC, Lin CY, Wu MH, Chuang CH, Kao CX, Jeng HY, Lin GW, Ling TY, Chang TS, Huang YH. A Yes-Associated Protein (YAP) and Insulin-Like Growth Factor 1 Receptor (IGF-1R) Signaling Loop Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma. Cancers (Basel). 2021 Jul 29;13(15):3812. 10. Zhuang WZ, Lin YH, Su LJ, Wu MS, Jeng HY, Chang HC, Huang YH, Ling TY. Mesenchymal stem/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications. J Biomed Sci. 2021 Apr 14;28(1):28. 11. Ngo MT, Jeng HY, Kuo YC, Diony Nanda J, Brahmadhi A, Ling TY, Chang TS, Huang YH. The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance. Int J Mol Sci. 2021 Feb 16;22(4):1931. 12. Weng CF, Huang CJ, Huang SH, Wu MH, Tseng AH, Sung YC, Lee HH, Ling TY. New International Association for the Study of Lung Cancer (IASLC) Pathology Committee Grading System for the Prognostic Outcome of Advanced Lung Adenocarcinoma. Cancers (Basel). 2020 Nov 18;12(11):3426. 13. Weng CF, Huang CJ, Wu MH, Lee HH, Ling TY. Co-Expression of Coxsackievirus/Adenovirus Receptors and Desmoglein 2 in Lung Adenocarcinoma: A Comprehensive Analysis of Bioinformatics and Tissue Microarrays. J Clin Med. 2020 Nov 18;9(11):3693. doi: 10.3390/jcm9113693. PMID: 33217893; PMCID: PMC7698609. 14. Huang AP, Hsu YH, Wu MS, Tsai HH, Su CY, Ling TY, Hsu SH, Lai DM. Potential of stem cell therapy in intracerebral hemorrhage. Mol Biol Rep. 2020 Jun;47(6):4671-4680. 15. Tsai TH, Ling TY, Lee CH. Adoption of Regulations for Cell Therapy Development: Linkage Between Taiwan and Japan. Clin Transl Sci. 2020 Nov;13(6):1045-1047. 16. Chiu PC, Liou HC, Ling TY, Shen LJ. Development of a Neuroprotective Erythropoietin Modified with a Novel Carrier for the Blood-Brain Barrier. Neurotherapeutics. 2020 Jul;17(3):1184-1196. 17. Sun YJ, Hsu CH, Ling TY, Liu L, Lin TC, Jakfar S, Young IC, Lin FH. The preparation of cell-containing microbubble scaffolds to mimic alveoli structure as a 3D drug-screening system for lung cancer. Biofabrication. 2020 Mar 27;12(2):025031. 18. Chao TL, Gu SY, Lin PH, Chou YT, Ling TY, Chang SY. Characterization of Influenza A Virus Infection in Mouse Pulmonary Stem/Progenitor Cells. Front Microbiol. 2020 Jan 21;10:2942. 19. Lin SC, Liou YM, Ling TY, Chuang YH, Chiang BL. Placenta-Derived Mesenchymal Stem Cells Reduce the Interleukin-5 Level Experimentally in Children with Asthma. Int J Med Sci. 2019 Sep 20;16(11):1430-1438. 20. Weng CF, Chen LJ, Lin CW, Chen HM, Lee HH, Ling TY, Hsiao FY. Association between the risk of lung cancer and influenza: A population-based nested case-control study. Int J Infect Dis. 2019 Nov;88:8-13. 21. Su LJ, Lin HH, Wu MS, Pan L, Yadav K, Hsu HH, Ling TY, Chen YT, Chang HC. Intracellular Delivery of Luciferase with Fluorescent Nanodiamonds for Dual-Modality Imaging of Human Stem Cells. Bioconjug Chem. 2019 Aug 21;30(8):2228-2237. 22. Liou YM, Wei TY, Ling TY, Lin SC, Yang YH, Chiang BL, Chuang YH. Differential effects of mesenchymal stem cells on T cells isolated from childhood allergies and autoimmune diseases. Allergy. 2019 Oct;74(10):2006-2010. Patent 1. 林泰元、陳耀昌、侯勝茂、嚴孟祿、黃彥華、吳孟學 (2013/12) 新發明I419971號: 一種成體幹細胞之組織分解、細胞黏附與萃取暨培養技術。 2. 楊台鴻、林泰元、李亦宸、陳啟瑞 (2013/02) 新發明I384067號: 快速篩選生醫材料對細胞影響之細胞培養盤。 3. Yu J, Yu A and Ling TY (2007) Isolated pulmonary stem cells, which are slowly dividing cells forming individual colonies in vitro, express the marker Oct-4 and undergo terminal differentiation into a mature phenotype; useful for generating new cells to replace diseased and damaged body tissues related methods and kits of parts. US patient 20070087332